Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | STAT6 | P42226 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18539112 | 1.00 | HSD17B10 (0.47) | HSD17B10SLC6A9S1PR1ITGB3ITGA2B | |
| SCHEMBL29299536 | 1.00 | HSD17B10 (0.47) | HSD17B10SLC6A9S1PR1ITGB3ITGA2B | |
| SCHEMBL29404629 | 0.83 | — | — | |
| SCHEMBL13510843 | 0.83 | — | — | |
| SCHEMBL173508 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1GAAALDH1A1 | |
| Tetraxetan SCHEMBL18018 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1GAAALDH1A1 | |
| Tetraxetan SCHEMBL2635294 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1GAAALDH1A1 | |
| SCHEMBL6848102 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1GAAALDH1A1 | |
| SCHEMBL321989 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1GAAALDH1A1 | |
| Tetraxetan SCHEMBL2017956 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312430-A1 | Method of Preparing or Synthesizing Polyazamacrocycle Derivatives | THERAPHARM GMBH (CH) | 2008-12-18 | — | — | US | disclosed |
| US-20080312430-A1 | Method of Preparing or Synthesizing Polyazamacrocycle Derivatives | THERAPHARM GMBH (CH) | 2008-12-18 | — | — | US | disclosed |
| US-20080312430-A1 | Method of Preparing or Synthesizing Polyazamacrocycle Derivatives | THERAPHARM GMBH (CH) | 2008-12-18 | — | — | US | disclosed |
| EP-1812453-A1 | METHOD OF PREPARING OR SYNTHESIZING POLYAZAMACROCYCLE DERIVATIVES | Therapharm GmbH (CH) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006045546-A1 | METHOD OF PREPARING OR SYNTHESIZING POLYAZAMACROCYCLE DERIVATIVES | THERAPHARM GMBH (CH) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312430-A1 | Method of Preparing or Synthesizing Polyazamacrocycle Derivatives | POLI, PARP1, DHPS | HSD17B10 1028/4885SLC6A9 4481/4885S1PR1 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.